CA2849765C - Hybrid constant regions - Google Patents

Hybrid constant regions Download PDF

Info

Publication number
CA2849765C
CA2849765C CA2849765A CA2849765A CA2849765C CA 2849765 C CA2849765 C CA 2849765C CA 2849765 A CA2849765 A CA 2849765A CA 2849765 A CA2849765 A CA 2849765A CA 2849765 C CA2849765 C CA 2849765C
Authority
CA
Canada
Prior art keywords
igg
hybrids
retain
regions
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2849765A
Other languages
English (en)
French (fr)
Other versions
CA2849765A1 (en
Inventor
J. Yun Tso
Naoya Tsurushita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JN Biosciences LLC
Original Assignee
JN Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JN Biosciences LLC filed Critical JN Biosciences LLC
Publication of CA2849765A1 publication Critical patent/CA2849765A1/en
Application granted granted Critical
Publication of CA2849765C publication Critical patent/CA2849765C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2849765A 2011-09-26 2012-09-26 Hybrid constant regions Active CA2849765C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539416P 2011-09-26 2011-09-26
US61/539,416 2011-09-26
PCT/US2012/057393 WO2013049254A1 (en) 2011-09-26 2012-09-26 Hybrid constant regions

Publications (2)

Publication Number Publication Date
CA2849765A1 CA2849765A1 (en) 2013-04-04
CA2849765C true CA2849765C (en) 2021-10-19

Family

ID=47996377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2849765A Active CA2849765C (en) 2011-09-26 2012-09-26 Hybrid constant regions

Country Status (6)

Country Link
US (2) US8952134B2 (cg-RX-API-DMAC7.html)
EP (1) EP2760891B1 (cg-RX-API-DMAC7.html)
JP (1) JP6205363B2 (cg-RX-API-DMAC7.html)
CN (1) CN103974977A (cg-RX-API-DMAC7.html)
CA (1) CA2849765C (cg-RX-API-DMAC7.html)
WO (1) WO2013049254A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013049254A1 (en) 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
CN104583239B (zh) 2012-05-10 2018-09-18 生物蛋白有限公司 多特异单克隆抗体
EP2880057A4 (en) * 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
EP3041862B1 (en) * 2013-09-05 2020-05-06 IGM Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
CN106132994A (zh) * 2014-03-05 2016-11-16 Ucb生物制药私人有限公司 多聚体Fc蛋白
UY36021A (es) * 2014-03-05 2015-09-30 Ucb Biopharma Sprl Proteìnas fc multimèricas
WO2015167948A1 (en) 2014-04-30 2015-11-05 Albert Einstein College Of Medicine Of Yeshiva University Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
IL308212A (en) * 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
CA2980751A1 (en) * 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CA2981183A1 (en) 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
HK1245675A1 (zh) 2015-04-17 2018-08-31 Igm Biosciences, Inc. 多价人免疫缺陷病毒抗原结合分子及其用途
GB201515745D0 (en) * 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
RU2018130525A (ru) * 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
CA3030659A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
WO2018187702A2 (en) * 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
IL270366B1 (en) 2017-05-08 2025-09-01 Adimab Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
EP3759229A4 (en) * 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
AU2019287720B2 (en) 2018-06-14 2025-08-28 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
CA3103414A1 (en) 2018-06-14 2019-12-19 Bioatla, Inc. Multi-specific antibody constructs
SG11202103720XA (en) * 2018-10-23 2021-05-28 Igm Biosciences Inc MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
CA3115547A1 (en) * 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
AU2020291922A1 (en) * 2019-06-14 2022-02-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cancer
EP4130047A4 (en) * 2020-02-27 2024-07-31 Huahui Health Ltd. SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES
KR102450007B1 (ko) * 2020-10-16 2022-10-04 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
EP4342908A4 (en) * 2021-06-17 2024-10-23 Fapon Biotech Inc. CHIMERIC IMMUNGLOBULIN
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
AU2024329875A1 (en) * 2024-01-02 2025-07-17 Gempharmatech Co., Ltd Animal model generating humanized antibody and construction method thereof
KR20250173023A (ko) * 2024-05-30 2025-12-10 주식회사 아이엠바이오로직스 J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체
CN119638846B (zh) * 2025-01-09 2025-11-04 康复大学青岛中心医院 uMtCK抗体或其抗原结合片段

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
AU2001257445B2 (en) * 2000-04-28 2006-11-02 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
CN1911965B (zh) * 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2005047602A1 (en) * 2003-11-13 2005-05-26 Dsm Ip Assets B.V. Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems
CN101778867A (zh) * 2007-06-08 2010-07-14 地中海大学 用于治疗胰腺肿瘤的组合物和方法
WO2013049254A1 (en) 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions

Also Published As

Publication number Publication date
US20150073130A1 (en) 2015-03-12
EP2760891B1 (en) 2018-11-07
EP2760891A4 (en) 2015-06-24
JP2015501291A (ja) 2015-01-15
CA2849765A1 (en) 2013-04-04
WO2013049254A1 (en) 2013-04-04
EP2760891A1 (en) 2014-08-06
US20130089547A1 (en) 2013-04-11
CN103974977A (zh) 2014-08-06
JP6205363B2 (ja) 2017-09-27
US8952134B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
CA2849765C (en) Hybrid constant regions
IN2015DN01361A (cg-RX-API-DMAC7.html)
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
IL272572A (en) Antibody compositions for tumor treatment
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG10201407935YA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
UA103499C2 (ru) Антитело против интерлейкина-17 (ил-17) человека и его применение
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2011051327A3 (en) Small antibody-like single chain proteins
MX2013007392A (es) Anticuerpo modificado con vida media mejorada.
WO2018218056A8 (en) ANTIBODIES COMPRISING MODIFIED HEAVY CHAIN CONSTANT CHAIN REGIONS
IN2012DN02535A (cg-RX-API-DMAC7.html)
WO2008003103A3 (en) Novel multivalent immunoglobulins
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
NZ715896A (en) Humanized or chimeric cd3 antibodies
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
WO2013061098A3 (en) Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes
WO2008017963A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2011008517A3 (en) Immunoglobulin fc polypeptides
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2009048537A3 (en) Humanized antibody
NZ603581A (en) Anti-gd2 antibodies
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170623